MF1.F CANBRIDGE PHARM.DL-00001
- Market cap
- EUR 105M
- P/E
- -
- P/B
- 0.92x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MF1.F undervalued?
Graham numberThe Graham number of CANBRIDGE PHARM.DL-00001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CANBRIDGE PHARM.DL-00001 fundamental analysis
No fundamental analysis for CANBRIDGE PHARM.DL-00001 yet.
CANBRIDGE PHARM.DL-00001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It al…
Full company profileCANBRIDGE PHARM.DL-00001 financial statements
CANBRIDGE PHARM.DL-00001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 31.2M | 79.0M | 103M | 85.1M | 50.0M |
| Gross Profit | 18.8M | 48.9M | 64.2M | 54.3M | 37.3M |
| Operating Income | -655M | -450M | -365M | -340M | -91.6M |
| EBITDA | - | -455M | -341M | -407M | 29.2M |
| Net Income | -1.08B | -483M | -379M | -443M | 14.8M |
| EPS | -2.54 | -1.14 | -0.89 | -1.04 | 0.03 |
| Balance Sheet | |||||
| Total Assets | 893M | 702M | 395M | 117M | 165M |
| Total Liabilities | 199M | 393M | 435M | 591M | 507M |
| Shareholders' Equity | 693M | 309M | -39.8M | -474M | -342M |
| Cash & Short-term Investments | 746M | 451M | 125M | 10.0M | 66.6M |
| Cash Flow | |||||
| Operating Cash Flow | -587M | -281M | -278M | -122M | -38.2M |
| Capital Expenditure | 5.33M | 34.8M | 40.9M | 105K | 6.00K |
| Free Cash Flow | -592M | -316M | -319M | -123M | -38.2M |
| Ratios | |||||
| ROE | -155.3% | -156.7% | - | - | - |
| ROA | -120.7% | -68.9% | -95.8% | -378.9% | 9.0% |
| Net Profit Margin | -3,456.3% | -612.2% | -368.3% | -520.1% | 29.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CANBRIDGE PHARM.DL-00001 dividends
CANBRIDGE PHARM.DL-00001 has not paid dividends in the last 6 fiscal years.
Who owns CANBRIDGE PHARM.DL-00001
- Insiders 41.91%
- Institutions 9.04%
- Public & others 49.05%
- Shares outstanding 597M
- Free float 326M
CANBRIDGE PHARM.DL-00001 company profile
- Company name
- CANBRIDGE PHARM.DL-00001
- Ticker
- MF1.F
- ISIN
- KYG1821D1097
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- December
- Address
- Suzhou Industrial Park, Building 21, Suzhou, China
- Phone
- 86 10 6478 0016
- Website
- canbridgepharma.com
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; and CAN204 to treat Duchenne muscular dystrophy. The company has a license agreement with Mirum Pharmaceuticals, Inc. for the development, manufacture, and commercialization of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.
CANBRIDGE PHARM.DL-00001 management
10- Dr. Qun Xue M.B.A., Ph.D.Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board · born 1970
- Ms. Lillian ZhangSenior Director & Head of Finance Operations and Controller
- Mr. Joe ShenChief Operating Officer
- Ms. Qian MaVice President, Company Secretary & General Counsel
- Ms. Chris ChenSenior Vice President of Human Resources
- Dr. Gerald F. Cox M.D., Ph.D.Chief Development Strategist & Interim Chief Medical Officer · born 1959
- Ms. Rebecca ZhangChief Regulatory Advisor
- Dr. Jeff Kou Ph.D.Head of Clinical Operations and Senior Director of R&D Strategy & Portfolio Management
- Dr. Jason WestHead of Global Gene Therapy Research
- Mr. Will WangExecutive Director of Production